Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.

Abstract

The role of aromatase inhibitors combined with gonadotropin-releasing hormone analog in metastatic male breast cancer patients remains unknown. In this retrospective study we evaluated the activity of letrozole combined with a gonadotropin-releasing hormone analog as a first- or second-line therapy for metastatic male breast cancer patients. 19 men entered the study. We did not observe any grade 3 or 4 adverse events. 2 patients (10.5 %) had complete response, 7 patients (36.8 %) experienced a partial response, 7 patients (36.8 %) had stable disease lasting ≥ 6 months, and 3 patients (15.8 %) had progressive disease. Overall, the disease control rate was 84.2 %. Median progression-free survival was 12.5 months (95 % CI 8.2-16.9), median overall survival was 35.8 months (95 % CI 24.4-49.2), 1- and 2-year survival rates were 89.5 and 67 %, respectively. Interestingly, 3 out of 4 patients treated with the combination following disease progression while on aromatase inhibitor monotherapy confirmed or improved the best overall response observed in the first-line setting. The combination of letrozole and gonadotropin-releasing hormone analog is effective and safe in hormone-receptor positive, metastatic male breast cancer patients.

• Authors: Luigi Di Lauro, Patrizia Vici, Pietro Del Medico, Lucio Laudadio, Silverio Tomao, Diana Giannarelli, Laura Pizzuti, Domenico Sergi, Maddalena Barba, Marcello Maugeri-Saccà
• Journal: Breast cancer research and treatment (Breast Cancer Res Treat) Vol. 141 Issue 1 Pg. 119-23 (Aug 2013) ISSN: 1573-7217 [Electronic] Netherlands
• PMID: 23982884 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents, Hormonal
• Aromatase Inhibitors
• Estrogen Receptor Modulators
• Estrogens
• Nitriles
• Taxoids
• Triazoles
• Tamoxifen
• Goserelin
• Docetaxel
• Gonadotropin-Releasing Hormone
• Epirubicin
• Progesterone
• Letrozole
• Cyclophosphamide
• Fluorouracil
• Methotrexate

Topics

• Aged
• Antineoplastic Agents, Hormonal (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Aromatase Inhibitors (administration & dosage)
• Breast Neoplasms, Male (drug therapy, radiotherapy, surgery)
• Carcinoma, Ductal, Breast (drug therapy, radiotherapy, secondary, surgery)
• Carcinoma, Papillary (drug therapy, surgery)
• Chemotherapy, Adjuvant
• Combined Modality Therapy
• Cyclophosphamide (administration & dosage)
• Disease-Free Survival
• Docetaxel
• Epirubicin (administration & dosage)
• Estrogen Receptor Modulators (administration & dosage)
• Estrogens
• Fluorouracil
• Gonadotropin-Releasing Hormone (agonists)
• Goserelin (administration & dosage)
• Humans
• Kaplan-Meier Estimate
• Letrozole
• Male
• Mastectomy, Modified Radical
• Methotrexate
• Middle Aged
• Neoplasms, Hormone-Dependent (drug therapy, radiotherapy, surgery)
• Nitriles (administration & dosage)
• Progesterone
• Radiotherapy, Adjuvant
• Tamoxifen (administration & dosage)
• Taxoids (administration & dosage)
• Triazoles (administration & dosage)